Granted Patent
B2
US 12,208,126 · App. 18/165,770 · Granted Jan 28, 2025
Oncolytic viral vectors and uses thereof
Inventors:
Mitchell H. Finer (Cambridge, MA); Lorena Lerner (Cambridge, MA); Christophe Quéva (Cambridge, MA); Edward Kennedy (Cambridge, MA)
Assignee:
Virogin Biotech Canada Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
Claims (29)
1. A recombinant oncolytic herpes simplex virus (HSV) comprising
(i) a first micro-RNA (miRNA) target sequence cassette (miR-TS) cassette inserted into at least one ICP4 gene or at least one ICP4 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-124, miR-1, and miR-143;
(ii) a second miR-TS cassette inserted into the ICP27 gene or an ICP27 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-128, miR-219a, and miR-122; and
(iii) a third miR-TS cassette inserted into at least one ICP34.5 gene or at least one ICP34.5 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-219a, miR-204, and miR-128.
2. The recombinant oncolytic herpes simplex virus of claim 1 , wherein the recombinant oncolytic HSV further comprises a fourth miR-TS cassette inserted into UL8 and comprising: (a) at least 2 target sequences for each of miR-137, miR-208b, and miR-126; or (b) at least 2 target sequences for each of miR-137, miR-217, and miR-126.
3. The recombinant oncolytic herpes simplex virus of claim 1 , wherein replication of the recombinant oncolytic HSV is reduced in a non-cancerous cell compared to the replication of the recombinant oncolytic HSV in a cancerous cell of the same cell type, and wherein the non-cancerous cell and the cancerous cell are selected from the group consisting of a neuronal cell, a cardiac cell, a muscle cell, and a liver cell.
4. The recombinant oncolytic herpes simplex virus of claim 1 , wherein:
(a) the first miR-TS cassette: comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 852; comprises the nucleic acid sequence of SEQ ID NO: 852; or consists of the nucleic acid sequence of SEQ ID NO: 852;
(b) the second miR-TS cassette: comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 853; comprises the nucleic acid sequence of SEQ ID NO: 853; or consists of the nucleic acid sequence of SEQ ID NO: 853; or
(c) the third miR-TS cassette: comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 854; comprises the nucleic acid sequence of SEQ ID NO: 854; or consists of the nucleic acid sequence of SEQ ID NO: 854.
5. The recombinant oncolytic herpes simplex virus of claim 2 , wherein the fourth miR-TS cassette comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 855; comprises the nucleic acid sequence of SEQ ID NO: 855; or consists of the nucleic acid sequence of SEQ ID NO: 855.
6. The recombinant oncolytic herpes simplex virus of claim 1 , wherein each of the miR-TS cassettes is inserted into at least one UTR of said ICP4, ICP27, and ICP34.5 genes, wherein the at least one UTR is selected from a 5′ UTR or a 3′ UTR.
7. The recombinant oncolytic herpes simplex virus of claim 6 , wherein each of the miR-TS cassettes has a length of less than 1000 nucleotides.
8. The recombinant oncolytic herpes simplex virus of claim 1 , further comprising a heterologous polynucleotide sequence encoding one or more payload molecules.
9. The recombinant oncolytic herpes simplex virus of claim 8 , wherein the heterologous polynucleotide sequence encodes the payload molecule selected from the group consisting of IL-12, CCL4, and CXCL10.
10. The recombinant oncolytic herpes simplex virus of claim 8 , wherein the payload molecule comprises (a) an anti-FAP/anti-CD3 bispecific T cell engager or (b) an anti-PD1-Fc-41BBL protein.
11. A nucleic acid molecule encoding the recombinant oncolytic herpes simplex virus of claim 1 .
12. A viral stock comprising the recombinant oncolytic herpes simplex virus of claim 1 .
13. A composition comprising the recombinant oncolytic herpes simplex virus of claim 1 and a pharmaceutically acceptable carrier.
14. A method for killing a cancerous cell, comprising exposing the cancerous cell to the recombinant oncolytic herpes simplex virus of claim 1 under conditions sufficient for the oncolytic virus to infect and replicate within said cancerous cell, and wherein replication of the oncolytic virus within the cancerous cell results in cell death.
15. The method of claim 14 , wherein the cancerous cell has a reduced expression of a miRNA capable of binding to the one or more miRNA target sequences compared to the expression of the miRNA in a non-cancerous cell, and wherein the expression level of the miRNA in the cancerous cell is at least 5% less than the expression level the miRNA in the non-cancerous cell.
16. The method of claim 14 , wherein replication of the oncolytic virus is increased or maintained in cancerous cells with a reduced expression of the miRNA capable of binding to the one or more miRNA target sequences, and wherein the viral replication is at least 5% greater in the cancerous cells compared to the viral replication in the non-cancerous cell.
17. The method of claim 14 , wherein the cell is in vivo.
18. The method of claim 14 , wherein the cell is within a tumor.
19. A method for treating cancer in a subject in need thereof, comprising administering the recombinant oncolytic herpes simplex virus of claim 1 or a composition thereof.
20. The method of claim 19 , wherein the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human.
21. The method of claim 19 , wherein the oncolytic virus or the composition thereof is administered intravenously, subcutaneously, intratumorally, intramuscularly, or intranasally.
22. The method of claim 19 , wherein the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL).
23. The method of claim 22 , wherein the lung cancer is small cell lung cancer or non-small cell lung cancer, or wherein the liver cancer is hepatocellular carcinoma (HCC).
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 27, 2023
From: ONCORUS, INC.
To: VIROGIN BIOTECH CANADA LTD.
Reel/Frame 065670/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 24, 2023
From: FINER, MITCHELL H.; LERNER, LORENA; QUÉVA, CHRISTOPHE; KENNEDY, EDWARD
To: ONCORUS, INC.
Reel/Frame 063094/0616 →
Continuity (4)
Continuation
16633653
Provisional Application
62686802
· Jun 19, 2018
Provisional Application
62537359
· Jul 26, 2017
References Cited (400)
US 5059538A
· Nozaki et al.
· 1991
[cited by applicant]
US 5399363A
· Liversidge et al.
· 1995
[cited by applicant]
US 5466468A
· Schneider et al.
· 1995
[cited by applicant]
US 5543158A
· Gref et al.
· 1996
[cited by applicant]
US 5641515A
· Ramtoola
· 1997
[cited by applicant]
US 5658724A
· DeLuca
· 1997
[cited by applicant]
US 5725871A
· Illum
· 1998
[cited by applicant]
US 5756353A
· Debs
· 1998
[cited by applicant]
US 5759814A
· Burke et al.
· 1998
[cited by applicant]
US 5780045A
· McQuinn et al.
· 1998
[cited by applicant]
US 5804212A
· Illum
· 1998
[cited by applicant]
US 5804413A
· DeLuca
· 1998
[cited by applicant]
US 5837532A
· Preston et al.
· 1998
[cited by applicant]
US 5849571A
· Glorioso et al.
· 1998
[cited by applicant]
US 5849572A
· Glorioso et al.
· 1998
[cited by applicant]
US 5879934A
· DeLuca
· 1999
[cited by applicant]
US 5998174A
· Glorioso et al.
· 1999
[cited by applicant]
US 6071742A
· Tracy et al.
· 2000
[cited by applicant]
US 6261552B1
· DeLuca
· 2001
[cited by applicant]
US 6469155B1
· Fiume et al.
· 2002
[cited by applicant]
US 6653447B1
· Cosman et al.
· 2003
[cited by applicant]
US 7078029B2
· DeLuca
· 2006
[cited by applicant]
US 7473418B2
· Yu et al.
· 2009
[cited by applicant]
US 7514252B2
· Chiocca et al.
· 2009
[cited by applicant]
US 7531167B2
· Glorioso et al.
· 2009
[cited by applicant]
US 8129167B2
· Cosman
· 2012
[cited by applicant]
US 8546553B2
· Terns et al.
· 2013
[cited by applicant]
US 8957036B2
· Cascio et al.
· 2015
[cited by applicant]
US 8980246B2
· Kirn
· 2015
[cited by applicant]
US 9157071B2
· Campadelli et al.
· 2015
[cited by applicant]
US 9226977B2
· Kirn
· 2016
[cited by applicant]
US 9593347B2
· Glorioso, III et al.
· 2017
[cited by applicant]
US 9919062B2
· Kirn
· 2018
[cited by applicant]
US 20020037575A1
· Speck
· 2002
[cited by applicant]
US 20020187126A1
· Blaho et al.
· 2002
[cited by applicant]
US 20080008686A1
· Yao
· 2008
[cited by applicant]
US 20080289058A1
· Cascio et al.
· 2008
[cited by applicant]
US 20100076057A1
· Sontheimer et al.
· 2010
[cited by applicant]
US 20100104578A1
· Shafren
· 2010
[cited by applicant]
US 20130071430A1
· Nakamura et al.
· 2013
[cited by applicant]
US 20130156808A1
· Jonjic
· 2013
[cited by applicant]
US 20130202639A1
· Kousoulas et al.
· 2013
[cited by applicant]
US 20140363469A1
· Meyers et al.
· 2014
[cited by applicant]
US 20150017121A1
· Becher et al.
· 2015
[cited by applicant]
US 20170000832A1
· Shafren et al.
· 2017
[cited by applicant]
US 20170107537A1
· Glorioso, III et al.
· 2017
[cited by applicant]
US 20180169271A1
· Cantwell et al.
· 2018
[cited by applicant]
US 20180318365A1
· Yeung et al.
· 2018
[cited by applicant]
US 20220380735A1
· Kennedy et al.
· 2022
[cited by applicant]
US 20230115116A1
· Greenberg et al.
· 2023
[cited by applicant]
AU 2012322999B2
· 2017
[cited by applicant]
AU 2017206231B2
· 2019
[cited by applicant]
CA 2476724A1
· 2003
[cited by applicant]
CA 2850575A1
· 2013
[cited by applicant]
CA 2928956A1
· 2015
[cited by applicant]
CN 105008918A
· 2015
[cited by applicant]
CN 105793425A
· 2016
[cited by applicant]
EP 2591796A1
· 2013
[cited by applicant]
EP 2766035B1
· 2018
[cited by applicant]
EP 3351261A1
· 2018
[cited by applicant]
EP 3426271A1
· 2019
[cited by applicant]
EP 3441084A1
· 2019
[cited by applicant]
JP 2001508294A
· 2001
[cited by applicant]
JP 2003518080A
· 2003
[cited by applicant]
JP 2009060907A
· 2009
[cited by applicant]
KR 20030047667A
· 2003
[cited by applicant]
WO WO9102788A1
· 1991
[cited by applicant]
WO WO9604394A1
· 1996
[cited by applicant]
WO WO9815637A1
· 1998
[cited by applicant]
WO WO9906583A1
· 1999
[cited by applicant]
WO WO9960142A2
· 1999
[cited by applicant]
WO WO2005092374A2
· 2005
[cited by applicant]
WO WO2006017914A1
· 2006
[cited by applicant]
WO WO2007025097A2
· 2007
[cited by applicant]
WO WO2008021207A2
· 2008
[cited by applicant]
WO WO2008141151A2
· 2008
[cited by applicant]
WO WO2008143875A1
· 2008
[cited by applicant]
WO WO2009111892A1
· 2009
[cited by applicant]
WO WO2009130479A2
· 2009
[cited by applicant]
WO WO2009144755A1
· 2009
[cited by applicant]
WO WO2009148488A2
· 2009
[cited by applicant]
WO WO2009150431A1
· 2009
[cited by applicant]
WO WO2010011961A2
· 2010
[cited by applicant]
WO WO2010054108A2
· 2010
[cited by applicant]
WO WO2010054154A2
· 2010
[cited by applicant]
WO WO2010135242A1
· 2010
[cited by applicant]
WO WO2011125469A1
· 2011
[cited by applicant]
WO WO2011130749A2
· 2011
[cited by applicant]
WO WO2012006181A2
· 2012
[cited by applicant]
WO WO2012054726A1
· 2012
[cited by applicant]
WO WO2012149470A1
· 2012
[cited by applicant]
WO WO2012164565A1
· 2012
[cited by applicant]
WO WO2013004396A2
· 2013
[cited by applicant]
WO WO2013053775A1
· 2013
[cited by applicant]
WO WO2013098244A1
· 2013
[cited by applicant]
WO WO2013109604A1
· 2013
[cited by applicant]
WO WO2013126794A1
· 2013
[cited by applicant]
WO WO2013141680A1
· 2013
[cited by applicant]
WO WO2013142578A1
· 2013
[cited by applicant]
WO WO2014107599A2
· 2014
[cited by applicant]
WO WO2014204729A1
· 2014
[cited by applicant]
WO WO2015009952A1
· 2015
[cited by applicant]
WO WO2015066042A1
· 2015
[cited by applicant]
WO WO2016141320A2
· 2016
[cited by applicant]
WO WO2017059168A1
· 2017
[cited by applicant]
WO WO2017096201A1
· 2017
[cited by applicant]
WO WO2017103290A1
· 2017
[cited by applicant]
WO WO2017103291A1
· 2017
[cited by applicant]
WO WO2017118864A1
· 2017
[cited by applicant]
WO WO2017118865A1
· 2017
[cited by applicant]
WO WO2017118866A1
· 2017
[cited by applicant]
WO WO2017118867A1
· 2017
[cited by applicant]
WO WO2017132552A1
· 2017
[cited by applicant]
WO WO2017156349A1
· 2017
[cited by applicant]
WO WO2018026872A1
· 2018
[cited by applicant]
WO WO2018027316A1
· 2018
[cited by applicant]
WO WO2018049248A1
· 2018
[cited by applicant]
WO WO2018049261A1
· 2018
[cited by applicant]
WO WO2018085461A1
· 2018
[cited by applicant]
WO WO2018118819A2
· 2018
[cited by applicant]
WO WO2018118967A1
· 2018
[cited by applicant]
WO WO2018127713A1
· 2018
[cited by applicant]
WO WO2019014623A1
· 2019
[cited by applicant]
WO WO2019023483A1
· 2019
[cited by applicant]
WO WO2020186355A1
· 2020
[cited by applicant]
WO WO2020186356A1
· 2020
[cited by applicant]
WO WO2021072310A1
· 2021
[cited by applicant]
WO WO2021101796A1
· 2021
[cited by applicant]
Adamiak et al., “Herpes Simplex Virus Type 2 Glycoprotein G is Targeted by the Sulfated Oligo- and Polysaccharide Inhibitors of Virus Attachment to Cells,” Journal of Virology, 81(24), 13424-13434 (2007).
[cited by applicant]
Aghi et al., “Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.,” Oncogene, 27: 4249-4254 (2008).
[cited by applicant]
Akashi, H., Gene expression and molecular evolution. Curr Opin Genet Dev. Dec. 2001;11(6):660-666.
[cited by applicant]
Akimoto et al., “A new delivery system for 5-fluorouracil using prodrug and converting enzyme,” J. Ophthalmol., 86(5): 581-586 (2002).
[cited by applicant]
Alayo et al., “Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses,” Sci Rep. (2020) 10:5095, 11 pages.
[cited by applicant]
Amelio et al., “A Chromatin Insulator-Like Element in the Herpes Simplex Virus Type 1 Latency-Associated Transcript Region Binds CCCTC-Binding Factor and Displays Enhancer-Blocking and Silencing Activities,” J. of Virol…
[cited by applicant]
Ames, H. M., et al. “MicroRNA profiling of low grade glial and glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b,” Mod Pathol., Feb. 2017, 30(2): 204-216, doi:10.1038/modpathol.2016.177,…
[cited by applicant]
Anderson et al., “Pseudotyping of Glycoprotein D-Deficient Herpes Simplex Virus Type 1 with Vesicular Stomatitis Virus Glycoprotein G Enable Mutant Virus Attachment and Entrv,” Journal of Virologv, 74(5): 2481-2487 (Mar…
[cited by applicant]
Argnani, R., et al., “Replication-competent herpes simplex vectors: design and applications,” Gene Therapy (2005), vol. 12, pp. S170-S177.
[cited by applicant]
Asano et al., “Humanization of the Bispecific Epidermal Growth Factor Receptor X CD3 Diabody and Its Efficacy as a Potential Clinical Reagent,” Clin. Cancer Res., 12(13): 4036-4042 (Jul. 1, 2006).
[cited by applicant]
Assi et al., “Gene Therapy for Brain Tumors: Basic Developments and Clinical Implementation,” Neurosci. Lett., Oct. 11, 2012, 527(2): 71-77, 14 pages.
[cited by applicant]
Aurelian, L. et al., “Oncolytic viruses as immunotherapy: progress and remaining challenges,” OncoTargets and Therapy, 9, pp. 2627-2637 (May 2016).
[cited by applicant]
Ausländer, S. et al., “A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression,” Molecular BioSystems, 6, pp. 807-814, DOI: 10.1039/b923076a (2010).
[cited by applicant]
Baek et al., “Bispecific Adapter-Mediated Retargeting of a Receptor-Restricted HSV-1 Vector to CEA-Bearing Tumor Cells,” Molecular Therapy, 19(3): 507-514 (Mar. 2011).
[cited by applicant]
Baertsch et al., “MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus,” Cancer Gene Therapy, 21(9), 373-380 (Sep. 2014).
[cited by applicant]
Banerjee, et al., “Herpes Simplex Virus: The Hostile Guest that Takes Over Your Home,” Frontiers in Microbiology, 11:733, pp. 1-18 (2020).
[cited by applicant]
Barrangou et al., “CRISPR provides acquired resistance against viruses in prokaryotes,” Science. 315(5819):1709-12.2007.
[cited by applicant]
Beilstein, K. et al., “Conditional Control of Mammalian Gene Expression by Tetracycline-Dependent Hammerhead Ribozymes,” ACS Synthetic Biology, 4, pp. 526-534,dx.doi.org/10.1021/sb500270h (2015).
[cited by applicant]
Bennett et al., “Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer,” Cancer Gene Therapy, 9: 935-945 (2002).
[cited by applicant]
Black, et al., “Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing,” Cancer Res. Apr. 1, 2001; 61(7):3022-3026.
[cited by applicant]
Broberg et al., “Immune Response to Herpes Simplex Virus and 134.5 Deleted HSV Vectors ,” Current Gene Therapy, 5: 523-530 (2005).
[cited by applicant]
Brouns et al., “Small CRISPR RNAs guide antiviral defense in prokaryotes,” Science, Aug. 15, 2008;321(5891):960-964 (9 total pages).
[cited by applicant]
Brown, S. M. et al., “ICP 34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro,” Journal of General Virology, 75, 3679-3686 (1994).
[cited by applicant]
Burton, E. A., et al., “Use of the Herpes Simplex Viral Genome to Construct Gene Therapy Vectors,” Methods in Molecular Medicine, Humana Press, vol. 76, pp. 1-31 (Jan. 2003).
[cited by applicant]
Bzik et al., “Nucleotide Sequence of a Region of the Herpes Simplex Virus Type 1 gB Glycoprotein Gene: Mutations Affecting Rate of Virus Entry and Cell Fusion, ” Virology, 37: 185-190 (1984).
[cited by applicant]
Cai et al., “Linker-Insertion Nonsense and Restriction-Site Deletion Mutations of the gB Glycoprotein Gene of Herpes Simplex Virus Type 1,” Journal of Virology, 61(3): 714-721 (Mar. 1987).
[cited by applicant]
Camacho, L. H., et al., “Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies”, Journal of Clinical Oncology (2004); 22(14_suppl): 2505; Abstract O…
[cited by applicant]
Campadelli-Fiume et al., “Rethinking herpes simplex virus: the way to oncolytic agents,” Rev. Med. Viral., 21: 213-226 (2011).
[cited by applicant]
Cao et al., “A functional study of miR-124 in the developing neural tube,” Genes & Development, 21: 531-536 (2007).
[cited by applicant]
Cattaneo et al., “Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded” Nature Reviews Microbiology, Jul. 2008, 6(7): 529-540, 25 pages.
[cited by applicant]
Cawood, R. et al., “Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells,” PLOS Pathogens, May 2009, vol. 5(5): e1000440,10 pages.
[cited by applicant]
Cheadle et al., “Cloning and expression of the variable regions of mouse myeloma protein MOPC315 in
[cited by applicant]
Chen, S-H. et al., “Neither LAT nor Open Reading Frame P Mutations Increase Expression of Spliced or Intron-Containing ICP0 Transcripts in Mouse Ganglia Latently Infected with Herpes Simplex Virus”, Journal of Virology,…
[cited by applicant]
Cheng, J., et al., “Novel transcription regulatory sequences and factors of the immune evasion protein ICP47 (US12) of herpes simplex viruses,” Virology Journal (2020), vol. 17:101, 11 pages, doi: 10.1186/s12985-020-013…
[cited by applicant]
Cherenkova et al., “Generation of recombinant adenoviruses and lentiviruses expressing angiogenic and neuroprotective factors using Gateway cloning technology,” Cell Transplantology and Tissue Engineering, 2012, vol. 7,…
[cited by applicant]
Chihara, N., et al., “Induction and Transcriptional Regulation of the Co-Inhibitory Gene Module in T Cells,” Nature 2018, 558 (7710): 454-459, doi:10.1038/s41586-018-0206-z (Jun. 2018) (36 total pages).
[cited by applicant]
Chiocca, et al., “First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma,” DOI: 10.1200/JCO.2021.39.15_suppl.2009, Journal of Clinical Oncology, vol. 39, No. 15_…
[cited by applicant]
Chou, J. et al., “Mapping of Herpes Simplex Virus-1 Neurovirulence to γ134.5, a Gene Nonessential for Growth in Culture,” Science, vol. 250, Issue 4985, pp. 1262-1266, doi: 10.1126/science.2173860 (Nov. 1990).
[cited by applicant]
Chumakov, P. M., Oncolytic viruses, Institute of Molecular Biology. V.A. Engelgard RAS, 10th Zilber lecture, Nov. 19, 2015, w/ English translation, 4 pages.
[cited by applicant]
Cocchi et al., “The Ectodomain of a Novel Member of the Immunoglobulin Subfamily Related to the Poliovirus Receptor Has the Attributes of a Bona Fide Receptor for Herpes Simplex Virus Types 1 and 2 in Human Cells,” Jour…
[cited by applicant]
Cocchi et al., “The Herpes Simplex Virus JMP Mutant Enters Receptor-Negative J Cells through a Novel Pathway Independent of the Known Receptors nectin1, HveA, and nectin2,” Journal of Virology, 78(9): 4720-4729 (May 200…
[cited by applicant]
Cong et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems”, Science, Feb. 2013, 339: 819-823.
[cited by applicant]
Conner et al., “A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein,” Gene Therapy, …
[cited by applicant]
Connolly et al., “Potential Nectin-1 Binding Site on Herpes Simplex Virus Glycoprotein D,” Journal of Virology, 79(2): 1282-1295 (Jan. 2005).
[cited by applicant]
Connolly et al., Structure-Based Analysis of the Herpes Simplex Virus Glycoprotein D Binding Site Present on Herpevirus Entry Mediator HveA (HVEM), Journal of Virology 76(21):10894-10904 (Nov. 2002).
[cited by applicant]
Co-pending U.S. Appl. No. 60/917,752, inventor Cascio; et al, filed May 14, 2007, 22 pages.
[cited by applicant]
Co-pending U.S. Appl. No. 61/325,137, inventor Glorioso; et al, filed Apr. 16, 2010, 67 pages.
[cited by applicant]
Co-pending U.S. Appl. No. 61/847,405, inventor Glorioso; et al, filed Jul. 17, 2013, 48 pages.
[cited by applicant]
Currier et al., “Efficacy and Safety of the Oncolytic Herpes Simplex VirusrRp450 Alone and Combined With Cyclophosphamide,” Molecular Therapy, May 2008, 16(5): 879-885, 18 total pages.
[cited by applicant]
Darmanis, S. et al., “Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma,” Cell Reports, 21, 1399-1410, Supplemental Information, https://doi.org/10.1016/j.celrep.…
[cited by applicant]
De Gruijl et al., “Arming oncolytic viruses to leverage antitumor immunity,” Expert Opinion on Biological Therapy, (2015) 15:7, 959-971.
[cited by applicant]
Deltcheva et al., “Crispr RNA maturation by trans-encoded small RNA and host factor RNase III,” Nature, Mar. 31, 2011; 471(7340): 602-607 (19 total pages).
[cited by applicant]
Deluca et al., “Nucleotide Sequences of Herpes Simplex Virus Type 1 (HSV-1) Affecting Virus Entry, Cell Fusion, and Production of Glycoprotein gB (VP7),” Virology, 122: 411-423 (1982).
[cited by applicant]
Delwar et al., “Tumour-specific triple-regulated oncolytic herpes virus to target glioma,” Oncotarget, 2016, vol. 7, No. 19, pp. 28658-28669.
[cited by applicant]
Desai et al., “Incorporation of the Green Fluorescent Protein into the Herpes Simplex Virus Type 1 Capsid,” Journal of Virology, 72(9): 7563-7568 (Sep. 1998).
[cited by applicant]
Dmitrieva et al., “Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy,” Clin. Cancer Res., 17(6): 1362-1372 (2011).
[cited by applicant]
Doronina et al., “Site-specific release of nascent chains from ribosomes at a sense codon,” Molecular and Cellular Biology, 28(13): 4227-4239 (2008).
[cited by applicant]
Edge et al., “A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication,” Molecular Therapy, 16(8): 1437-1443 (Aug. 2008).
[cited by applicant]
Eisenring et al., “IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46,” Nat Immunol., 2010;11(11):1030-8, including Online Methods, 1 page.
[cited by applicant]
El-Andaloussi, N., et al., “Generation of an Adenovirus-Parvovirus Chimera with Enhanced Oncolytic Potential”, Journal of Virology, The American Society for Microbiology, vol. 86, No. 19, pp. 10418-10431 (Oct. 2012).
[cited by applicant]
Esko et al., “Animal Cell Mutants Defective in Glycosaminoglycan biosynthesis,” Proc. Natl. Acad. Sci. USA, 82: 3197-3201 (May 1985).
[cited by applicant]
European Patent Office, European Search Report in European Patent Application No. 17155129.4, dated May 30, 2017, 9 pages.
[cited by applicant]
Extended European Search Report and Search Opinion for European Application No. 20184441.2, dated Jan. 12, 2021, 7 pages.
[cited by applicant]
Extended European Search Report for Application EP22161034.8, mailed Oct. 17, 2022, 7 pages.
[cited by applicant]
Extended European Search Report issued by the European Patent Office for Application No. 14859119.1, dated Apr. 19, 2017, 10 pages.
[cited by applicant]
Fan et al., “Mapping sites of herpes simplex virus type 1 glycoprotein D that permit insertions and impact gD and gB receptors usage,” Sci Rep. Mar. 3, 2017; 7:43712, 12 pages.
[cited by applicant]
Fecci et al., “Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function,” Clin Cancer Res., 2007;13(7):2158-2167.
[cited by applicant]
Ferretti, E., et al. “MicroRNA profiling in human medulloblastoma.” International Journal of Cancer, vol. 124, Issue 3, pp. 568-577 (2009).
[cited by applicant]
Frampton et al., “Equine Herpesvirus 1 Enters Cells by Two Different Pathways, and Infection Requires the Activation of the Cellular Kinase ROCK1,” Journal of Virology, 81(20): 10879-10889 (2007).
[cited by applicant]
Friedman et al., “Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies ” Molecular Therapy, 17(7): 1125-1135 (2009).
[cited by applicant]
Friedman et al., “Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas,” N Engl J Med., 384(17):1613-1622 (Apr. 2021).
[cited by applicant]
Friedman et al., “Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression,” Sci. Rep. (2018) 8:13930, 10 pages.
[cited by applicant]
Fu et al., “Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells,” Molecular Therapy, Feb. 2012, vol. 20, No. 2, pp. 339-346, published online Dec. 6, 2011, doi:10.1038…
[cited by applicant]
Fujioka et al., “Interleukin-18 protects mice against acute herpes simplex virus type 1 infection,” Journal of Virology, 73(3): 2401-2409 (1999).
[cited by applicant]
Fuller et al., “Anti-glycoprotein D Antibodies That Permit Adsorption but Block Infection by Herpes Simplex Virus 1 Prevent Virion-cell Fusion at the Cell Surface,” Proc. Natl. Acad. Sci. USA, 84: 5454-5458 (Aug. 1987).
[cited by applicant]
Fuller et al., “Neutralizing Antibodies Specific for Glycoprotein H of Herpes Simplex Virus Permit Viral Attachment to Cells but Prevent Penetration,” Journal of Virology, 63(8): 3435-3443 (Aug. 1989).
[cited by applicant]
Garneau, J.E. et al. (2010). “The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA,” Nature 468:67-71 and 1 p. methods.
[cited by applicant]
Gasiunas et al., “Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria,” PNAS, Sep. 25, 2012, vol. 109, No. 39, pp. 15539-15540.
[cited by applicant]
Gaur et al., “Characterization of microRNA expression levels and their biological correlates in human cancer cell lines,” Cancer Res., 67(6): 2456-2468 (2007).
[cited by applicant]
GenBank Accession No. MN136523.1; American Type Culture Collection (ATCC) Catalog No. VR-39, 52 pages, Aug. 11, 2019.
[cited by applicant]
GenBank Reference No. D00627.1, Human coxsackievirus A9 genomic RNA, complete genome, strain: Griggs, Dec. 14, 2007 (online) (retrieved on Jul. 21, 2022) Retrieved from https://www.ncbi.nlm.nih.gov/nuccore/221214 (4 tot…
[cited by applicant]
GenBank Reference No. KT161266.1, Coxsackievirus A21 isolate JN12377/SD/CHN/2012/CVA21, complete genome, Dec. 15, 2015 (online) (retrieved on Jul. 21, 2022) Retrieved from https://www.ncbi.nlm.nih.gov/nuccore/930578064 …
[cited by applicant]
GenBank Reference No. M33854.1, Coxsackievirus B3 (CVB3) complete genome, Jun. 29, 1999 (online) (retrieved on Jul. 21, 2022) Retrieved from https://www.ncbi.nlm.nih.gov/nuccore/323419 (4 total pages).
[cited by applicant]
Geraghty et al., “Entry of Alphaherpesviruses Mediated by Poliovirus Receptor-Related Protein 1 and Poliovirus Receptor,” Science, 280: 1618-1620 (Jun. 5, 1998).
[cited by applicant]
Gibson, et al., “Enzymatic assembly of DNA molecules up to several hundred kilobases.” Nature Methods (Apr. 12, 2009); 6(5): 343-345.
[cited by applicant]
Gierasch et al., “Construction and Characterization of Bacterial Artificial Chromosomes Containing HSV-1 Strains 17 and KOS,” Journal of Virological Methods, 135: 197-206 (2006).
[cited by applicant]
Gossen and Bujard, “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters”. Proc Natl Acad Sci U S A, Jun. 15, 1992; 89(12): 5547-5551.
[cited by applicant]
Grandi P., et al., “Design and application of oncolytic HSV vectors for glioblastoma therapy,” Expert Rev. Neurother. Apr. 2009, 9(4): 505-517, 23 total pages.
[cited by applicant]
Grossman et al., “Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States,” Clinical Cancer Research 2010, 16: 2443-2449, 12 total pages.
[cited by applicant]
Gu, F., “Diagnostic techniques for viral, rickettsial and chlamydial diseases,” Beijing Medical University—China Union Medical University Joint Press, 1993, 6 pages.
[cited by applicant]
Gubanova et al., “Oncolytic viruses in the therapy of gliomas,” Mol Biol (Mosk), 46(6), pp. 874-886 (Nov.-Dec. 2012), ISSN: 0026- 8984 (English abstract) (1 page).
[cited by applicant]
Guzman et al., “Expression of entry receptor nectin-1 of Herpes simplex virus 1 and/or Herpes simplex virus 2 in normal and neoplastic human nervous system tissues,” Acta Virol. 2006; 50(1):59-66.
[cited by applicant]
Hale et al., “RNA-Guided RNA Cleavage by a CRISPR RNA-Cas Protein Complex,” Cell 139, 945-956, Nov. 25, 2009.
[cited by applicant]
He et al., “Targeting Glioblastoma Stem Cells: Cell Surface Markers,” Current Medicinal Chemistry, 19: 6050-6055 (2012).
[cited by applicant]
Henke et al., “microRNA-122 stimulates translation of hepatitis C virus RNA,” EMBO J. (2008) 27:3300-3310.
[cited by applicant]
Highlander et al., “Identification of mar Mutations in Herpes Simplex Virus Type 1 Glycoprotein B Which Alter Antigenic Structure and Function in Virus Penetration,” Journal of Virology, 63(2): 730-738 (Feb. 1989).
[cited by applicant]
Hodi, F. S. et al. “Improved survival with ipilimumab in patients with metastatic melanoma.” New England Journal of Medicine 363.8 (2010): 711-723.
[cited by applicant]
Hong et al. “Ectopic matrix metalloproteinase 9 expression in human brain tumor cells enhances oncolytic HSV vector infection,” Gene Therapy 17:1200-1205 (2010).
[cited by applicant]
Ikeda, K. et al., Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses, Nature Medicine, vol. 5, No. 8, pp. 881-887 (Aug. 1999).
[cited by applicant]
International Preliminary Report on Patentability issued by the International Searching Authority for Application No. PCT/US2011/032923, dated Oct. 16, 2012, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability issued by the International Searching Authority for Application No. PCT/US2014/062676, dated May 3, 2016, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability, mailed Apr. 12, 2022, for International Application No. PCT/US2020/055133 (13 total pages).
[cited by applicant]
International Preliminary Report on Patentability, mailed Jan. 28, 2020, for International Application No. PCT/US2018/043938 (11 total pages).
[cited by applicant]
International Preliminary Report on Patentability, mailed Jul. 31, 2018, for International Application No. PCT/US2017/015417 (9 total pages).
[cited by applicant]
International Search Report and Written Opinion, dated May 19, 2017, for International Application No. PCT/US2017/015417 (15 total pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/075767 dated Jan. 10, 2023, 20 pages.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2011/032923, dated Mar. 28, 2012, 12 pages.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2014/062676, dated Dec. 23, 2014, 9 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Mar. 26, 2021, for International Application No. PCT/US2020/055133 (24 total pages).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2018/43938, dated Dec. 14, 2018, 16 pages.
[cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Apr. 5, 2017, for International Application No. PCT/US2017/015417 (15 total pages).
[cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Feb. 5, 2021, for International Application No. PCT/US2020/055133 (20 total pages).
[cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Nov. 3, 2022, for International Application No. PCT/US2022/075767 (4 total pages).
[cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Oct. 15, 2018, for International Application No. PCT/US2018/043938 (3 total pages).
[cited by applicant]
Iorio et al., “microRNA involvement in human cancer,” Carcinogenesis, 33(6): 1126-1133 (2012).
[cited by applicant]
Ishida et al., “Enhanced cytotoxicity with a novel system combining the paclitaxel-2′-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus,” Cancer Letters, 2…
[cited by applicant]
Ishino et al., “Oncolytric Virus Therapy with HSV-1 for Hematologic Malignancies,” Blood (2019), 134 (Supplement_1): 3242, 3 pages.
[cited by applicant]
Jackson et al., “Crystal structure of the CRISPR RNA-guided surveillance complex from Escherichia coli,” Science, Sep. 19, 2014; 345(6203): 1473-1479 (15 total pages).
[cited by applicant]
Jackson et al, “Insertion Mutations in Herpes Simplex Virus 1 Glycoprotein H Reduce Cell Surface Expression, Slow the Rate of Cell Fusion, or Abrogate Functions in Cell Fusion and Viral Entry,” Journal of Virology, 84(4…
[cited by applicant]
Jenkins et al., “Deletion of the Herpes simplex 1 internal repeat sequences affects pathogenicity in the mouse,” Frontiers in Bioscience, Oct. 1996, 1:a59-68, 17 total pages.
[cited by applicant]
Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science (Aug. 2012); 337(6096):816-821.
[cited by applicant]
Jinek et al., “RNA-programmed genome editing in human cells,” Elife. Jan. 29, 2013;2:e00471 (9 total pages).
[cited by applicant]
Junejo et al., “Deletions and Duplication in Internal Inverted Repeat Sequence of Long Region/Unique Sequence of Long Region (IRL/UL) of Herpes Simplex Virus Type-i (HSV-i) Genome are not Evidently Associated with Intra…
[cited by applicant]
Kaji et al., “Virus-free induction of pluripotency and subsequent excision of reprogramming factors,” Nature, Apr. 9, 2009, 458(7239): 771-775, 10 pages.
[cited by applicant]
Kambara et al., “An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor,” Cancer Res., 65(7): 2832-2839 (2005).
[cited by applicant]
Karpowicz et al., “E-Cadherin Regulates Neural Stem Cell Self-Renewal,” The Journal of Neuroscience, Mar. 25, 2009, 29(12): 3885-3896.
[cited by applicant]
Karsy et al., “Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme.,” Genes & Cancer, 3(1): 3-15 (2012).
[cited by applicant]
Katoh et al., “Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review),” International Journal of Molecular Medicine, 22: 271-275 (2008).
[cited by applicant]
Kaur et al., “Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress,” Curr Pharm Biotechnol., Jul. 2012; 13(9): 1842-1851 (19 total pages).
[cited by applicant]
Kelly et al., “Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting,” Journal of Virology, Feb. 2010, vol. 84, No. 3, pp. 1550-1562.
[cited by applicant]
Kelly et al., “Engineering microRNA responsiveness to decrease virus pathogenicity,” Nature Medicine, Nov. 2008, vol. 14, No. 11, pp. 1277-1283.
[cited by applicant]
Kennedy et al., “Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability,” Molecular Therapy: Oncolytics, vol. 18, pp. 476-490 (Sep. 2020).
[cited by applicant]
Ketzer, Patrick, et al., “Artificial riboswitches for gene expression and replication control of DNA and RNA viruses,” PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1318563111 , E554-E562 (Jan. 2014).
[cited by applicant]
Klysik et al., “Acyclovir in the Treatment of Herpes Viruses—A Review,” Curr Med Chem. 2020; 27(24):4118-4137.
[cited by applicant]
Kosovsky et al., “Herpes Simplex Virus 1 (HSV-1) Strain HSZP Glycoprotein B Gene: Comparison of Mutations among Strains Differing in Virulence,” Virus Genes, 20(1): 27-33 (2000).
[cited by applicant]
Krisky et al., “Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons,” Gene Therapy 5:1593-1603 (1998).
[cited by applicant]
Krisky et al., “Rapid method for construction of recombinant HSV gene transfer vectors,” Gene Therapy, 4: 1120-1125 (1997).
[cited by applicant]
Krummenacher et al., “Effects of Herpes Simplex Virus on Structure and Function of Nectin-1/HveC,” Journal of Virology, Mar. 2002, 76(5): 2424-2433.
[cited by applicant]
Kuan et al., “Increased Binding Affinity Enhances Targeting of Glioma Xenografts by EGFRVIII-Specific scFv,” Int. J. Cancer, 88: 962-969 (2000).
[cited by applicant]
Kumar et al., “Impaired microRNA processing enhances cellular transformation and tumorigenesis,” Nature Genetics, 39(5): 673-677 (2007).
[cited by applicant]
Kwon et al., “Soluble V Domain of Nectin-1/HveC Enables Entry of Herpes Simplex Virus Type 1 (HSV-1) into HSY-Resistant Cells by Binding to Viral Glycoprotein D,” Journal of Virology, Jan. 2006, 80(1): 138-148.
[cited by applicant]
Lavon et al., “Gliomas display a microRNA expression profile reminiscent of neural precursor cells,” Neuro-Oncology, 12(5): 422-433 (2010).
[cited by applicant]
Lee et al., “MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells,” Clin. Cancer Res., 15(16): 5126-5135 (2009).
[cited by applicant]
Lee et al., “Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors,” Molecular Therapy, 2010; 18(5):929-935.
[cited by applicant]
Li et al., “Identification of Functional Domains in Herpes Simplex Virus 2 Glycoprotein B,” Journal of Virology, Apr. 2006, vol. 80, No. 8, pp. 3792-3800.
[cited by applicant]
Li, J-M., et al., “MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells”, Virology Journal 2013, 10(1): 241, pp. 1-9, published Jul. 22, 2013, http://ww…
[cited by applicant]
Ligas et al., “A Herpes Simplex Virus Mutant in Which Glycoprotein D Sequences Are Replaced by beta-Galactosidase Sequences Binds to but Is Unable To Penetrate into Cells,” Journal of Virology, May 1988, 62(5): 1486-149…
[cited by applicant]
Lilley et al., “Multiple Immediate-Early Gene-Deficient Herpes Simplex Virus Vectors Allowing Efficient Gene Delivery to Neurons in Culture and Widespread Gene Delivery to the Central Nervous System In Vivo,” J. of Viro…
[cited by applicant]
Linde, et al., “Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis,” Journal of Neuro-Oncology, vol. 135, pp. 183-192 (2017).
[cited by applicant]
Liu B.L., et al., “ICP34.5 Deleted Herpes Simplex Virus with Enhanced Oncolytic, Immune Stimulating, and Anti-Tumour Properties,” Gene Therapy 2003, 10, pp. 292-303.
[cited by applicant]
Loakes et al., “5-Nitroindole as an universal base analogue,” Nucleic Acids Research, 1994, 22(20): 4039-4043.
[cited by applicant]
Lopez-Otin et al., “Emerging roles of proteases in tumour suppression,” Nat Rev Cancer, 2007, 7(10):800-808.
[cited by applicant]
Ma et al., “A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma,” World J Gastroenterol 9:463-467 (2003).
[cited by applicant]
Macdonald et al., “Genome Sequence of Herpes Simplex Virus 1 Strain KOS,” Journal of Virology, Jun. 2012, 86(11): 6371-6372.
[cited by applicant]
Maclean, A. R. et al., “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence,” Journal of Genera…
[cited by applicant]
Mali et al., “RNA-guided human genome engineering via Cas9”, Science. Feb. 15, 2013; 339(6121): 823-6. Epub Jan. 3, 2013.
[cited by applicant]
Mammoto et al., “Role of Collagen Matrix in Tumor Angiogenesis and Glioblastoma Multiforme Progression,” The American Journal of Pathology, 183(4): 1293-1305 (2013).
[cited by applicant]
Manickan et al., “Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.,” The Journal of Immunology, 155: 259-265 (1995).
[cited by applicant]
Manservigi, R., et al., “HSV Recombinant Vectors for Gene Therapy,” The Open Virology Journal, 2010, vol. 4, pp. 123-156.
[cited by applicant]
Marraffini and Sontheimer, “CRISPR Interference Limits Horizontal Gene Transfer in Staphylococci by Targeting DNA,” Science, Dec. 19, 2008; 322(5909): 1843-1845 (7 total pages).
[cited by applicant]
Martin, N. T., et al., “Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones”, Molecular Therapy, vol. 26, No. 6, pp. 1414-1422 (Jun. 2018).
[cited by applicant]
Mascanfroni, I. D., et al., “Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α,” Nature Medicine, vol. 21, No. 6, pp. 638-646, including Online Methods, doi:10.1038/nm.3868 (Jun. 2015), 12 …
[cited by applicant]
Mayo L., et al., “L-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation,” Brain (2016); 139(Pt 7):1939-1957.
[cited by applicant]
Mazzacurati et al., “Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV,” Molecular Therapy, Jan. 2015, 23(1): 99-107.
[cited by applicant]
McGeoch et al., “The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1,” J. Gen. Virol. (1988), 69, 1531-1574.
[cited by applicant]
Mckee et al., “Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector,” Cancer Research, 66(5): 2509-2513 (2006).
[cited by applicant]
Melancon et al., “Herpes Simplex Virus Type 1 gK Is Required for gB-Mediated Virus-Induced Cell Fusion, While neither gB and gK nor gB and UL20p Function Redundantly in Virion De-Envelopment,” J Virol. Jan. 2005; 79(1):…
[cited by applicant]
Menotti et al., “Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2,” Journal of Virology, Oct. 2008, 82(20): 10153-10161.
[cited by applicant]
Menotti, L., et al., “Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells,” PNAS 106:9039-9044 (2009).
[cited by applicant]
Metz et al., “Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing,” Protein Engineering, Design & Selection vol. 25 No. 10 pp. 571-580, 2012.
[cited by applicant]
Miao et al., “EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties,” Oncogene, 34(5): 558-567 (2015) (23 total pages).
[cited by applicant]
Miest et al., “ New viruses for cancer therapy: meeting clinical needs,” Nature Reviews Microbiology, Jan. 2014, 12(1): 23-34 , 29 pages.
[cited by applicant]
Miller et al., “Development of a Syngenic Murine 816 Cell Line-Derived Melanoma Susceptible to Destruction by Neuroattenuated HSV-1,” Molecular Therapy, 3(2), Feb. 2001, pp. 160-168.
[cited by applicant]
Milne et al., “Glycoprotein D Receptor-Dependent, Low-pH-Independent Endocytic Entry of Herpes Simplex Virus Type 1,” Journal of Virology, Jun. 2005, 79(11): 6655-6663.
[cited by applicant]
Mohyeldin et al., “Gene and viral therapy for glioblastoma: a review of clinical trials and future directions,” The Cancer Journal, 18(1): 82-88 (2012).
[cited by applicant]
Mok et al., “Matrix Metalloproteinases-1 and -8 Improve the Distribution and Efficacy of an Oncolytic Virus,” Cancer Res., 67(22): 10664-10668 (2007).
[cited by applicant]
Montgomery et al., “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family,” Cell 87:427-436 (1996).
[cited by applicant]
Mou, H., et al., Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence, Molecular Therapy, vol. 26, No. 5, pp. 1277-1286 (May 2018).
[cited by applicant]
Muggeridge, “Characterization of Cell-cell Fusion Mediated by Herpes Simplex Virus 2 glycoproteins gB, gD, gH and gL in Transfected Cells,” Journal of General Virology, 81: 2017-2027 (2000).
[cited by applicant]
Mulepati et al., “Crystal structure of a CRISPR RNA-guided surveillance complex bound to a ssDNA target,” Science, Sep. 19, 2014; 345(6203): 1479-1484 (15 total pages).
[cited by applicant]
Mullokandov et al. “High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries,” Nature Methods 2012, 9(8):840-846, 19 pages.
[cited by applicant]
Nakano et al., “Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor,” Virology 2011, 413: 12-18, 16 pages.
[cited by applicant]
Navaratnarajah et al., “Targeted Entry of Enveloped Viruses: Measles and Herpes Simplex Virus I” Curr. Opin. Virol., Feb. 2012, 2(1): 43-49, 11 pages.
[cited by applicant]
NCBI, “Chain A, Glycoprotein B From Herpes Simplex Virus Type 1” Database Entrez-Nucleotide, Accession No. 4L1R_A (Jun. 26, 2013). Retrieved on Mar. 5, 2018, 5 pages.
[cited by applicant]
NCBI, “glycoprotein B [Human herpesvirus 1],” Database Entrez-Nucleotide, Accession No. AAA91805 (Mar. 8, 1996). Retrieved on Mar. 5, 2018, 1 page.
[cited by applicant]
NCBI, “glycoprotein B [Human herpesvirus 1],” Database Entrez-Nucleotide, Accession No. AAF70301 (May 16, 2000). Retrieved on Mar. 5, 2018, 1 page.
[cited by applicant]
NCBI, “glycoprotein B [Human herpesvirus 2],” Database Entrez-Nucleotide, Accession No. ABU45427 (Nov. 29, 2007). Retrieved on Mar. 5, 2018, 2 pages.
[cited by applicant]
NCBI, “Herpes Simplex Virus Type 1 Gene for Glycoprotein gH,” Database GenBank Accession No. X03896 (Apr. 18, 2005). Retrieved on Mar. 5, 2018, 3 pages.
[cited by applicant]
NCBI, “Herpes Simplex Virus Type 1 Gene for Glycoprotein gH,” Database GenBank Accession No. X03896 (Jul. 26, 2016). Retrieved on Mar. 5, 2018, 3 pages.
[cited by applicant]
NCBI, “Human Herpesvirus 1 Complete Genome,” Database GenBank Accession No. X14112 (Oct. 23, 2008). Retrieved on Mar. 5, 2018, 70 pages.
[cited by applicant]
NCBI, “Human Herpesvirus 1 Strain KOS Glycoprotein B Gene,” Database GenBank Accession No. AF311740 (Jan. 24, 2001). Retrieved on Mar. 5, 2018, 2 pages.
[cited by applicant]
NCBI Reference Sequence: NC_001806.2, Human herpesvirus 1 strain 17, complete genome, Aug. 13, 2018, 62 pages.
[cited by applicant]
Nduom et al., “Glioblastoma Cancer Stem-like Cells—Implications for Pathogenesis and Treatment,” Cancer J., Jan. 2012, 18(1): 100-106, 16 pages.
[cited by applicant]
Nicola and Strauss, “Cellular and Viral Requirements for Rapid Endocytic Entry of Herpes Simplex Virus,” Journal of Virology, Jul. 2004, 78(14): 7508-7517.
[cited by applicant]
Nicola et al., “Roles for Endocytosis and Low pH in Herpes Simplex Virus Entry into HeLa and Chinese Hamster Ovary Cells,” Journal of Virology, May 2003, 77(9): 5324-5332.
[cited by applicant]
Nomura, Y. et al., “Synthetic mammalian riboswitches based on guanine aptazyme,” Chem. Commun., 48, 7215-7217, DOI: 10.1039/c2cc33140c (2012).
[cited by applicant]
Ocana et al., “A new regulatory loop in cancer-cell invasion,” Molecular Biology Organization, 9(6): 521-522 (2008).
[cited by applicant]
O'Day et al., “Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study,” Annals of Oncology, 2010 21:1712-1717.
[cited by applicant]
Omidfar et al., “Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in Camelus bactrianus,” Tumor Biology, 25:179-187 (2004).
[cited by applicant]
Omidfar et al., “Production of a Novel Camel Single-Domain Antibody Specific for the Type III Mutant EGFR,” Tumor Biology, 25: 296-305 (2004).
[cited by applicant]
Opalinska et al., “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications,” Nature Reviews, 1: 503-514 (2002).
[cited by applicant]
Padfield et al., “Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma,” Front Oncol. 2015; 5:5, 8 pages.
[cited by applicant]
Parker et al., “Oncolytic viral therapy of malignant glioma,” Neurotherapeutics: The Journal of the American Society for Experimental Neuro Therapeutics, 6: 558-569 (2009).
[cited by applicant]
Patriarca et al., “Epithelial cell adhesion molecule expression (CD326) in cancer: a short review,” Cancer Treatment Reviews, 38: 68-75 (2012).
[cited by applicant]
Payne et al., “The pathobiology of collagens in glioma,” Mol. Cancer Res., Oct. 2013, 11(10), 21 pages, doi: 10.1158/1541-7786.MCR-13-0236.
[cited by applicant]
Pertel et al., “Cell Fusion Induced by Herpes Simplex Virus Glycoproteins gB, gD, and gH-gL Requires a gD Receptor but Not Necessarily Heparan Sulfate,” Virology, 279: 313-324 (2001).
[cited by applicant]
Peters, Cole et al., “Designing herpes viruses as oncolytics,” Molecular Therapy—Molecular Therapy—Oncolytics (2015) 2, 15010; doi:10.1038/mto.2015.10 (14 total pages).
[cited by applicant]
Postic et al., “KNOTTIN: the database of inhibitor cystine knot scaffold after 10 years, toward a systematic structure modeling,” Nucleic Acids Res. Jan. 4, 2018; 46(D1): D454-D458.
[cited by applicant]
Power, A. T., et al., “Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy,” Gene Therapy, vol. 15, No. 10, pp. 772-779 (Mar. 2008).
[cited by applicant]
Qi, L.S. et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression,” Cell, Feb. 2013, 152(5): 1173-1183, doi: 10.1016/j.cell.2013.02.022 (22 pages).
[cited by applicant]
Raag and Whitlow, “Single-chain Fvs.,” FASEB (1995) 9(1):73-80.
[cited by applicant]
Ran et al., “Genome engineering using the CRISPR-Cas9 system,” Nat Protoc. Nov. 2013; 8(11):2281-2308 (49 total pages).
[cited by applicant]
Rauch et al., “Mutations in Herpes Simplex Virus Glycoprotein D Distinguish Entry of Free Virus from Cell-Cell Spread,” Journal of Virology, Dec. 2000, 74(24):11437-11446.
[cited by applicant]
Richard et al., “The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion,” PLoS Pathogens, 2017, 13(12), e1006741, 32 pages.
[cited by applicant]
Riddick et al., “Integration and analysis of genome-scale data from gliomas,” Nature Reviews—Neurology, 7: 439-450 (2011).
[cited by applicant]
Robertson, Lesley M. et al., “Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716,” Journal of General Virology, vol. 73, pp. 967-970 (1992).
[cited by applicant]
Russell, T., et al., Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISP/Cas9 nucleases, Journal of Virological Methods, 2015, vol. 213, pp. 18-25.
[cited by applicant]
Russell, T., et al., “Lytic Promoters Express Protein during Herpes Simplex Virus Latency,” PLOS Pathogens, doi: 10.1371/journal.ppat.1005729 (Jun. 2016), 20 pages.
[cited by applicant]
Saharkhiz-Langroodi and Holland, Identification of the Fusion-from-without Determinants of Herpes Simplex Virus Type 1 Glycoprotein B, Virology 227, 153-159 (1997).
[cited by applicant]
Sapranauskas et al., “The
[cited by applicant]